

Attorney Docket No. GC590-2-C1
USSN 10/663,450
Page 6

REMARKS

Claims 1-13, 26-34, and 88 – 95 are pending in the application. Claim 29 has been amended and claims 88 – 95 are new. The claims submitted with the preliminary amendment, which was filed concurrently with the application papers in the instant application have been subject to a restriction to claims directed to a process (Group I, claims 1 – 13, 26 – 24 and 36) and claims directed to a product (Group II, claims 83 – 85 and 87). Applicants have elected with traverse the claims denominated by Group I, which are directed to a process of increasing the secretion of a heterologous protein. Claims 83 – 85 and 87 have been withdrawn, and claims 14 – 25, 35, and 37 – 82 have been cancelled.


Applicants have amended claim 29 to correct a minor error. In addition, new claims have been submitted which depend from independent claim 1. New claims 88 – 90 are directed to a DNA binding domain that has at least 80%, at least 90% and at least 95% similarity, respectively, to a DNA binding domain set forth in Figure 10. Claims 91 and 92 define the binding domain represented in SEQ ID NO: 5 or SEQ ID NO: 6. Claims 93 and 94 are directed to heterologous proteins, which were listed in original claim 85. Claim 95 further limits a number of the elements recited in independent claim 1. No new matter has been introduced by these amendments.

Applicants believe that the amendments presented herein put the claims in condition for allowance. Issuance of a formal Notice of Allowance is respectfully requested. Should the Examiner have any questions or if a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (650) 846-7620.

Respectfully submitted,

Dated: Oct. 17, 2005

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
(650) 846-7500, Ext. 7620
Fax: (650) 845-6504


Lynn Marcus-Wyner
Reg. No. 34,869

GC590-2-C1 RR